MRD in AML is predictive, unless you are over age 60 and treated with decitabine

Assessment of MRD (minimal or measurable residual disease) has emerged as a powerful and predictive tool for outcomes in patients with acute leukemia. There are several methods of measuring MRD including detection of pathogenic mutations on next generation genomic profiles and the detection of driver transcripts by real-time quantitative polymerase chain reaction (PCR). More commonly, MRD is characterized by highly sensitive multiparameter flow cytometry which has allowed detection of leukemia cells to a level of 1:10^4 or 1:10^6.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research